Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

CGEN

Compugen Ltd

Dec 03 • 04:00PM ET

1.54

Dollar change +0.04
Percentage change 2.67	%

Healthcare • Biotechnology • Israel • NASD

Peers: MRNA VRTX ALLO CRSP FATE NTLA EDIT SGMO BLUE CLLS

| Held by: SPDW GWX QQQS

Scroll to Statements

Index	-	P/E	80.21	EPS (ttm)	0.02	Insider Own	5.38%	Shs Outstand	89.54M	Perf Week	9.22%
Market Cap	137.88M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	0.00%	Shs Float	84.72M	Perf Month	-9.94%
Income	1.60M	PEG	-	EPS next Q	0.07	Inst Own	13.44%	Short Float	1.56%	Perf Quarter	-21.83%
Sales	59.85M	P/S	2.30	EPS this Y	82.54%	Inst Trans	-2.41%	Short Ratio	5.08	Perf Half Y	-27.01%
Book/sh	0.68	P/B	2.28	EPS next Y	-354.54%	ROA	1.67%	Short Interest	1.32M	Perf Year	119.69%
Cash/sh	1.26	P/C	1.22	EPS next 5Y	-	ROE	2.81%	52W Range	0.70 - 3.03	Perf YTD	-22.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.14%	ROI	2.54%	52W High	-49.18%	Beta	2.60
Dividend TTM	-	Quick Ratio	4.14	Sales past 5Y	94.22%	Gross Margin	84.53%	52W Low	120.00%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	4.14	EPS Y/Y TTM	105.31%	Oper. Margin	17.67%	RSI (14)	47.33	Volatility	7.62% 7.02%
Employees	68	Debt/Eq	0.05	Sales Y/Y TTM	698.03%	Profit Margin	2.67%	Recom	1.00	Target Price	4.00
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	112.72%	Payout	-	Rel Volume	0.69	Prev Close	1.50
Sales Surprise	1235.94%	EPS Surprise	110.53%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	259.74K	Price	1.54
SMA20	-1.00%	SMA50	-7.17%	SMA200	-22.12%	Trades		Volume	180,035	Change	2.67%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-22	Downgrade	Jefferies	Buy → Hold	$2
May-26-20	Resumed	JMP Securities	Mkt Outperform	$18
May-13-20	Initiated	Stifel	Buy	$19
May-07-20	Initiated	SVB Leerink	Outperform
Apr-22-20	Initiated	ROTH Capital	Buy	$28
Mar-24-20	Initiated	SunTrust	Buy	$16
Jan-16-20	Initiated	Cantor Fitzgerald	Overweight	$10
Mar-29-18	Initiated	Oppenheimer	Outperform
Feb-01-16	Resumed	Oppenheimer	Outperform
Oct-15-15	Initiated	FBR Capital	Outperform	$14
Apr-23-15	Resumed	Jefferies	Buy	$11
Apr-21-15	Initiated	Oppenheimer	Outperform	$11
Feb-07-14	Initiated	MLV & Co	Buy	$14
Dec-28-09	Reiterated	Cantor Fitzgerald	Buy	$5 → $12
Jul-29-09	Initiated	Cantor Fitzgerald	Buy	$6.50

Show Previous Ratings

Nov-27-24 07:00AM	Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies (PR Newswire) +5.92%
Nov-13-24 02:08AM	Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... (GuruFocus.com)
Nov-12-24 11:05AM	Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates (Zacks) -8.05%
09:56AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Third Quarter 2024 Results (PR Newswire)
07:00AM	Loading…
Nov-11-24 07:00AM	Compugen to Participate in Stifel 2024 Healthcare Conference (PR Newswire)
Nov-05-24 09:00AM	Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 (PR Newswire)
Oct-29-24 07:00AM	Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (PR Newswire)
Oct-07-24 07:00AM	Compugen to Present New Clinical Data at SITC 2024 (PR Newswire)
Sep-11-24 12:00PM	Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Sep-09-24 07:00AM	Compugen to Present at Single Cell Genomics 2024 Conference (PR Newswire) +8.20%
Aug-29-24 07:00AM	Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +6.84%
Aug-26-24 12:20PM	Can Compugen (CGEN) Run Higher on Rising Earnings Estimates? (Zacks)
Aug-06-24 08:25AM	Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:22AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Compugen Reports Second Quarter 2024 Results (PR Newswire)
Jul-30-24 06:52AM	Compugen receives FDA approval for Phase I trial of solid tumour treatment (Clinical Trials Arena)
Jul-29-24 07:00AM	Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors (PR Newswire)
Jul-23-24 07:00AM	Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 (PR Newswire)
Jun-17-24 07:00AM	Compugen to Present at Upcoming Antibody Industrial Symposium (PR Newswire) -5.31%
Jun-04-24 09:55AM	Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-30-24 07:00AM	Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig (PR Newswire) -7.98%
May-21-24 08:08AM	Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +6.90%
May-20-24 11:52AM	CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -17.54%
08:10AM	Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Compugen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports First Quarter 2024 Results (PR Newswire)
May-16-24 07:00AM	Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential (PR Newswire)
May-15-24 09:57AM	Compugen Names David Silberman CFO (MT Newswires) +5.74%
07:00AM	Compugen Appoints David Silberman as Chief Financial Officer (PR Newswire)
07:00AM	Loading…
May-06-24 07:00AM	Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 (PR Newswire)
Apr-25-24 07:00AM	Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 (PR Newswire)
Apr-10-24 07:00AM	Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 (PR Newswire)
Apr-03-24 07:00AM	Compugen to Participate in Two Upcoming Investor Conferences (PR Newswire)
Mar-12-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice (Zacks)
Mar-11-24 07:00AM	Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy (PR Newswire) -5.44%
Mar-07-24 09:41AM	Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 07:00AM	Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 (PR Newswire)
Mar-05-24 11:53AM	CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -13.56%
07:16AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Fourth Quarter and Full Year 2023 Results (PR Newswire)
Feb-29-24 08:58AM	Is a Surprise Coming for Compugen (CGEN) This Earnings Season? (Zacks)
Feb-26-24 07:00AM	Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 (PR Newswire) +9.40%
Feb-21-24 12:00PM	Compugen (CGEN) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-20-24 07:00AM	Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 (PR Newswire)
Feb-15-24 07:00AM	Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer (PR Newswire)
Jan-08-24 07:05AM	Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer (PR Newswire) +6.86%
07:00AM	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Dec-19-23 10:11AM	Why Is Compugen (CGEN) Stock Up 189% Today? (InvestorPlace) +173.97%
07:10AM	Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer (PR Newswire)
07:05AM	Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology (PR Newswire)
07:00AM	Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program (Business Wire)
Dec-15-23 08:17AM	7 Promising Penny Stocks With the Potential to Defy Expectations (InvestorPlace)
Dec-05-23 09:40AM	Is Compugen (CGEN) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-08-23 04:41PM	Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.93% -7.23%
Nov-07-23 07:28AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance) -5.85%
07:00AM	Compugen Reports Third Quarter 2023 Results (PR Newswire)
Nov-06-23 07:00AM	Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy (PR Newswire)
Nov-03-23 04:35PM	Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Oct-31-23 09:00AM	Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer (PR Newswire) +10.95%
Oct-24-23 07:00AM	Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023 (PR Newswire) +6.44%
Oct-03-23 07:00AM	Compugen to Present at Single Cell Genomics 2023 Meeting (PR Newswire)
Oct-02-23 07:00AM	Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer (PR Newswire)
Sep-27-23 09:00AM	Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023 (PR Newswire)
Sep-14-23 09:40AM	Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-31-23 07:00AM	Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-29-23 09:40AM	Has Compugen (CGEN) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-10-23 12:13PM	Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:17AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance) -8.04%
07:00AM	Compugen Reports Second Quarter 2023 Results (PR Newswire)
Jul-24-23 07:00AM	Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023 (PR Newswire) -5.88%
Jul-17-23 07:00AM	Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party (PR Newswire)
Jun-22-23 07:00AM	Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study (PR Newswire) -7.89%
Jun-13-23 07:00AM	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Jun-05-23 07:00AM	Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer (PR Newswire) +6.67%
Jun-02-23 07:09AM	We Think Compugen (NASDAQ:CGEN) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey)
May-18-23 09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
May-15-23 07:10AM	Compugen: Q1 Earnings Snapshot (AP Finance) +10.02%
07:00AM	Compugen Reports First Quarter 2023 Results (PR Newswire)
May-11-23 07:00AM	Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023 (PR Newswire)
May-09-23 07:00AM	Compugen to Present at the JMP Securities Life Sciences Conference (PR Newswire)
May-01-23 07:00AM	Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023 (PR Newswire)
Apr-27-23 07:00AM	Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023 (PR Newswire)
Apr-26-23 07:00AM	Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting (PR Newswire)
Mar-15-23 07:00AM	Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023 (PR Newswire)
Mar-14-23 09:40AM	Is Certara (CERT) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-13-23 06:30AM	Compugen (NASDAQ:CGEN investor three-year losses grow to 90% as the stock sheds US$11m this past week (Simply Wall St.)
Mar-10-23 02:08AM	Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 07:00AM	Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-06-23 07:00AM	Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study (PR Newswire)
Feb-28-23 12:17PM	Why Compugen Shares Are Up Today (Motley Fool)
Feb-27-23 07:00AM	Compugen Reports Fourth Quarter and Full Year 2022 Results (PR Newswire)
Feb-14-23 07:00AM	Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3 (PR Newswire) +6.29%
Feb-13-23 07:00AM	Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023 (PR Newswire)
Feb-09-23 07:00AM	Compugen to Present at the SVB Securities Global Biopharma Conference (PR Newswire) -6.32%
Feb-08-23 05:25PM	Why Compugen Stock Got Slammed Today (Motley Fool) -10.30%
Jan-27-23 09:32AM	12 Best One Dollar Stocks to Buy According To Hedge Funds (Insider Monkey)
Jan-23-23 07:00AM	Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview (PR Newswire)
Dec-29-22 04:53PM	Why Shares of Compugen Rose on Thursday (Motley Fool) +5.23%

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEN

Compugen Ltd

Upgrade your FINVIZ experience